Previous 10 | Next 10 |
Merger to create a company focused on advancing Oruka’s portfolio of novel biologics that aim to redefine the standard of care for patients with chronic skin diseases Oruka, the third company founded based on assets generated by Paragon Therapeutics, expects to advance ORKA-001 and...
ARCA biopharma Inc. (ABIO) is expected to report for Q4 2023
2024-02-01 16:38:32 ET More on ARCA biopharma Financial information for ARCA biopharma Read the full article on Seeking Alpha For further details see: ARCA biopharma GAAP EPS of -$0.37
Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., Feb. 01, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a...
Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., Oct. 18, 2023 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applyi...
2023-07-21 16:30:29 ET ARCA biopharma press release ( NASDAQ: ABIO ): Q2 GAAP EPS of -$0.10. Cash and cash equivalents were $40.2 million as of June 30, 2023, compared to $42.4 million as of December 31, 2022. ARCA believes that its current cash and cash equivalents, c...
Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., July 21, 2023 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a...
2023-04-24 16:50:11 ET ARCA biopharma press release ( NASDAQ: ABIO ): Q1 GAAP EPS of -$0.09. Cash and cash equivalents were $40.9 million as of March 31, 2022, compared to $42.4 million as of December 31, 2022. ARCA believes that its current cash and cash equivalents, cons...
WESTMINSTER, Colo., April 24, 2023 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported first quarter 2023 financial results and ...
WESTMINSTER, Colo., Feb. 24, 2023 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported 2022 financial results and provided a corporat...
News, Short Squeeze, Breakout and More Instantly...
Bogota Financial Corp. (BSBK) is expected to report for Q2 2024 Capital Product Partners L.P. (CPLP) is expected to report $0.17 for Q2 2024 Colgate-Palmolive Company (CL) is expected to report $0.87 for Q2 2024 ARCA biopharma Inc. (ABIO) is expected to report for Q2 2024 Barnes G...
Bank of the James Financial Group Inc. (BOTJ) is expected to report for Q2 2024 Electrolux AB ADR (ELUXY) is expected to report $-0.18 for Q2 2024 Coca Cola Femsa S.A.B. de C.V. American Depositary Shares each representing 10 Units (each Unit consists of 3 Series B Shares and 5 Series L S...
NEW YORK, NY / ACCESSWIRE / May 22, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Squarespace, Inc. (NYSE:SQSP)'s sale...